Jan Bogaerts

Summary

Affiliation: EORTC Data Center
Country: Belgium

Publications

  1. doi request reprint Individual patient data analysis to assess modifications to the RECIST criteria
    Jan Bogaerts
    European Organization for Research and Treatment of Cancer Headquarters, Avenue Mounierlaan 83 11, Brussels, Belgium
    Eur J Cancer 45:248-60. 2009
  2. doi request reprint EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma
    Yassine Lalami
    Institut Jules Bordet, Brussels, Belgium
    Radiother Oncol 105:238-40. 2012
  3. doi request reprint Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial
    Saskia Litière
    European Organisation for Research and Treatment of Cancer, Brussels, Belgium
    Lancet Oncol 13:412-9. 2012
  4. ncbi request reprint Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
  5. ncbi request reprint Clinical trial design limitations in head and neck squamous cell carcinomas
    Hwan Jung Yun
    EORTC Data Center, Brussels, Belgium
    Curr Opin Oncol 19:210-5. 2007
  6. doi request reprint Design issues in head and neck clinical trials: a statistician's perspective
    Catherine Fortpied
    EORTC Headquarters, Brussels, Belgium
    Anticancer Drugs 22:682-7. 2011

Detail Information

Publications6

  1. doi request reprint Individual patient data analysis to assess modifications to the RECIST criteria
    Jan Bogaerts
    European Organization for Research and Treatment of Cancer Headquarters, Avenue Mounierlaan 83 11, Brussels, Belgium
    Eur J Cancer 45:248-60. 2009
    ..Two key issues that required careful, data-based assessment were the maximum number of lesions that should be assessed at each evaluation and the added value of requiring confirmation of response...
  2. doi request reprint EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma
    Yassine Lalami
    Institut Jules Bordet, Brussels, Belgium
    Radiother Oncol 105:238-40. 2012
    ....
  3. doi request reprint Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial
    Saskia Litière
    European Organisation for Research and Treatment of Cancer, Brussels, Belgium
    Lancet Oncol 13:412-9. 2012
    ..Compared with BCT, MRM resulted in better local control, but did not affect overall survival or time to distant metastases. We report 20-year follow-up results...
  4. ncbi request reprint Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
    ..A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients...
  5. ncbi request reprint Clinical trial design limitations in head and neck squamous cell carcinomas
    Hwan Jung Yun
    EORTC Data Center, Brussels, Belgium
    Curr Opin Oncol 19:210-5. 2007
    ..It provides critical analysis of their methodology in order to facilitate future trial design...
  6. doi request reprint Design issues in head and neck clinical trials: a statistician's perspective
    Catherine Fortpied
    EORTC Headquarters, Brussels, Belgium
    Anticancer Drugs 22:682-7. 2011
    ..targeted population? Is there a concern for lack of equipoise and if so, how will it affect the trial results? What are the key elements that need to be taken into consideration when choosing, defining, and measuring the primary endpoint?..